BhavanaKondaMD

Oncology • Columbus, OH

Physician

Join to view full profile

Dr. Konda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Konda's full profile

Already have an account?

Office
2050 Kenny Rd
Tower 10th Floor
Columbus, OH 43221
Phone+1 614-293-8629

Fax+1 614-293-3112

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2012 - 2015
University of Miami Hospital and Clinics/Holy Cross HospitalResidency, Internal Medicine, 2009 - 2012
Osmania Medical College NTR UHSClass of 2007

Certifications & Licensure

OH State Medical License 2015 - 2026
FL State Medical License 2009 - 2013
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer Start of enrollment: 2020 Feb 10
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

28 citations
Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Malcolm H. Squires, Patrick J. Worth, Bhavana Konda, Manisha H. Shah, Mary Dillhoff
Pancreas. 2020-03-01
68 citations
Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial
Benedito A. Carneiro, Bhavana Konda, R. Costa, Ricardo Costa, Vinay Sagar
The Journal of Clinical Endocrinology and Metabolism. 2019-12-01
1 citations
Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer.
Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar
The Journal of Clinical Endocrinology and Metabolism. 2024-08-12

Journal Articles

Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors
Neil Saunders, David Strosberg, Jill Onesti, Carl R Schmidt, Manisha Shah, Mary Dillhoff, Lawrence A Shirley, Bhavana Konda, Annals of Surgical Oncology

Lectures

First real-world experience of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) since US FDA approval.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Preview of the 93rd American Thyroid Association Annual MeetingJuly 1st, 2024